The multi-center study is evaluating the use of Cofactor's OncoPrism test in predicting head and neck cancer patients' response to immunotherapy with other tumor types to follow.
Researchers presented interim results from the pilot PEER study of Aromasin, leuprolide, and Keytruda for HR-positive, HER2-negative advanced breast cancer.
The firm presented evidence that its DetermaIO gene expression test can help predict which bladder cancer patients are likely to respond to immune checkpoint inhibitors.
The firm presented data at the AACR annual meeting that demonstrates its approach to treating HER2-positive solid cancers with engineered CAR macrophages.
Researchers said that the score further may identify patients whose treatment resistance may be overcome with combination strategies targeting certain cells.
The company plans to transition its DetermaIO test from research to clinical use and to launch a new research product for immunotherapy monitoring by the end of this year.
The firm highlighted a new study exploring immune-related gene expression in ovarian cancer and gave an update on its lead diagnostic candidate for head and neck tumors.
The company has partnered with Hospital Infantil Universitario Nino Jesus to further develop the autologous treatment, Celyvir, for metastatic solid tumors.
